NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)vsRegeneron Pharmaceuticals Inc (REGN)
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
$22.80
+4.30%
HEALTHCARE · Cap: $2.66B
REGN
Regeneron Pharmaceuticals Inc
$781.49
-1.48%
HEALTHCARE · Cap: $80.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 218053% more annual revenue ($15.53B vs $7.12M). REGN leads profitability with a 27.9% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 66/100 (B-).
NAMS
Avoid24
out of 100
Grade: F
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NAMS.
Margin of Safety
+44.4%
Fair Value
$1404.34
Current Price
$781.49
$622.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -32.0% — below average capital efficiency
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : NAMS
The strongest argument for NAMS centers on Debt/Equity, Altman Z-Score.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : NAMS
The primary concerns for NAMS are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
NAMS profiles as a value stock while REGN is a growth play — different risk/reward profiles.
REGN carries more volatility with a beta of 0.19 — expect wider price swings.
REGN is growing revenue faster at 16.7% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (66/100 vs 24/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NewAmsterdam Pharma Company N.V. Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
NewAmsterdam Pharma Company N.V. is a forward-looking biotechnology firm focused on the development of innovative therapies for cardiometabolic diseases, leveraging its proprietary technology platform to address critical unmet medical needs. With an advanced clinical development pipeline and a strategic commitment to reshaping treatment approaches, the company stands poised to significantly influence the healthcare landscape. Guided by a seasoned management team, NewAmsterdam offers a compelling investment opportunity for institutional investors aimed at facilitating transformative healthcare solutions that enhance patient outcomes while ensuring sustainable growth in the biopharmaceutical arena.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?